

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

BOSTON SCIENTIFIC CORP. and)	
BOSTON SCIENTIFIC NEUROMODULATION)	
CORP.,)	
)	
Plaintiffs and Counter-)	
Defendants,)	
)	C.A. No. 16-1163 (CFC) (CJB)
v.)	CONSOLIDATED
)	
NEVRO CORP.,)	DEMAND FOR JURY TRIAL
)	
Defendant and)	
Counterclaimant.)	

**NEVRO CORP.’S ANSWER, AFFIRMATIVE DEFENSES, AND
COUNTERCLAIMS TO THIRD AMENDED COMPLAINT**

Defendant Nevro Corp. (“Nevro”), by and through its undersigned counsel, hereby submits this Answer, Affirmative Defenses, and Counterclaims to the Third Amended Complaint of Plaintiffs Boston Scientific Corp. (“BSC”) and Boston Scientific Neuromodulation Corp. (“BSNC”) (collectively, “Boston Scientific”) (D.I. 789). Pursuant to Federal Rule of Civil Procedure 8(b)(3), Nevro denies each and every allegation in Boston Scientific’s Third Amended Complaint except those expressly admitted below.

OVERVIEW OF THE ACTION

1. This paragraph contains statements to which no response is required. To the extent any response is required, Nevro admits that Boston Scientific purports to bring an action for patent infringement and theft of trade secrets. Nevro denies any remaining allegations in this paragraph.

2. Nevro denies that it has infringed any valid and enforceable claims of U.S. Patent No. 7,496,404 (“the ’404 patent”); U.S. Patent No. 8,682,447 (“the ’447 patent”); U.S.

Patent No. 6,993,384 (“the ’384 patent”); U.S. Patent No. 7,853,330 (“the ’330 patent”); U.S. Patent No. 7,822,480 (“the ’480 patent”); U.S. Patent No. 6,381,496 (“the ’496 patent”); U.S. Patent No. 7,177,690 (“the ’690 patent”); and U.S. Patent No. 9,162,071 (“the ’071 patent”) (collectively, the “Asserted Patents”) via the manufacture, use, sale, offer to sell, exportation, and/or importation, in whole or in part, of the Senza[®] Spinal Cord Stimulation System, the Senza II[™] Spinal Cord Stimulation System, or the Senza[®] Omnia[™] Spinal Cord Stimulation System (collectively, the “Senza[®] Systems”).

3. Nevro denies that it has acquired or used confidential Boston Scientific documents.

THE PARTIES

4. Admitted.

5. Nevro admits that BSNC is a Delaware corporation with its principal place of business at 25155 Rye Canyon Loop, Valencia, California 91355. Nevro lacks sufficient knowledge or information to admit or deny the remaining allegations in this paragraph, and on that basis denies those allegations.

6. Admitted.

JURISDICTION AND VENUE

7. This paragraph contains statements to which no response is required. To the extent any response is required, Nevro admits that Boston Scientific purports to bring this action under the patent laws of the United States, pursuant to Title 35 of the United States Code, but denies that Boston Scientific’s claims have any merit.

8. Nevro admits that this Court has subject matter jurisdiction over the patent infringement claims asserted in Boston Scientific’s Third Amended Complaint under 28 U.S.C. §§ 1331 and 1338(a). Nevro denies any remaining allegations in this paragraph.

9. Denied.

10. Nevro admits that this Court has personal jurisdiction over Nevro for purposes of this litigation. Nevro denies any remaining allegations in this paragraph.

11. Nevro admits that venue is proper in this District for purposes of this litigation.

BOSTON SCIENTIFIC'S BACKGROUND

12. Nevro admits that Boston Scientific is a medical device manufacturer, and that Boston Scientific sells Spinal Cord Stimulation (“SCS”) systems for the treatment of chronic pain. Nevro lacks sufficient knowledge or information to admit or deny the remaining allegations in this paragraph, and on that basis denies those allegations.

13. Nevro admits, on information and belief, that Boston Scientific sells SCS systems that include the term “Precision” in the product name. Nevro lacks sufficient knowledge or information to admit or deny the remaining allegations in this paragraph, and on that basis denies those allegations.

14. Nevro denies that Boston Scientific developed and patented core technologies that are essential to SCS systems, and that Boston Scientific’s technologies form the foundation of every SCS system on the market, including Nevro’s Senza® Systems. Nevro lacks sufficient knowledge or information to admit or deny the remaining allegations in this paragraph, and on that basis denies those allegations.

THE NEVRO SYSTEMS

15. Nevro admits that its Senza® I system is as described in documents submitted by Nevro to the FDA and SEC, but denies this paragraph to the extent it is inconsistent or incomplete with respect to those documents.

16. Nevro denies that it launched the Senza[®] I system in Europe and Australia in the same year. Otherwise, admitted.

17. Nevro admits that its Senza[®] II system is as described in documents submitted by Nevro to the FDA and SEC, but denies this paragraph to the extent it is inconsistent or incomplete with respect to those documents.

18. Nevro admits that on November 5, 2019, it issued a press release announcing that its Senza[®] Omnia[™] had received approval from the FDA and that international approvals are expected in Europe during the first half of 2020 and Australia during the latter part of 2020. Nevro further admits that its Senza[®] Omnia[™] is as described in documents submitted by Nevro to the FDA and SEC, but denies the remainder of this paragraph to the extent it is inconsistent or incomplete with respect to those documents.

19. Nevro admits that C.C.C. Del Uruguay S.A. (“CCC”) is a manufacturer of Nevro’s implantable pulse generators (“IPGs”). Nevro denies that CCC currently manufactures Nevro’s external chargers, trial simulators, and programmer wands. Nevro admits that CCC has a manufacturing facility in Montevideo, Uruguay.

20. Nevro admits that Vention Medical Design and Development, Inc. (“Vention”) is a manufacturer of Nevro’s IPGs. Nevro admits that Vention has a manufacturing facility in the United States.

21. Nevro admits that Stellar Technologies, Inc. is the single-source supplier of Nevro’s percutaneous leads. Nevro lacks sufficient knowledge or information to admit or deny the remaining allegations in this paragraph, and on that basis denies those allegations.

22. Nevro admits that EaglePicher Medical Power LLC is currently the single-source supplier of batteries for Nevro’s IPGs. Nevro lacks sufficient knowledge or information

to admit or deny the remaining allegations in this paragraph, and on that basis denies those allegations.

23. Nevro admits that Pro-Tech Design and Manufacturing, Inc. (“Pro-Tech”) is the single-source supplier for conducting the inspection, labeling, packaging and sterilization of Nevro’s Senza[®] Systems. Nevro admits that Pro-Tech’s tender of the Senza[®] Systems for delivery, FCA (Incoterms 2000) includes Pro-Tech’s Santa Fe Springs, California facility. Nevro lacks sufficient knowledge or information to admit or deny the remaining allegations in this paragraph, and on that basis denies those allegations.

THE ASSERTED PATENTS

24. Nevro admits that it received copies of the Asserted Patents at least upon service of the First Amended Complaint. Nevro denies any remaining allegations in this paragraph.

25. Nevro admits that its February 29, 2016 Form 10-K filing contained the statement quoted in this paragraph. Nevro admits that Boston Scientific, Nevro, Medtronic, and St. Jude are competitors in the SCS market. Nevro denies any remaining allegations in this paragraph.

26. Nevro admits that it participated in an FDA-monitored randomized controlled trial in a head-to-head comparison against Boston Scientific’s Precision[™] SCS system in which Nevro’s Senza[®] System and paresthesia-free HF10[™] therapy was determined by the FDA to be clinically superior to Boston Scientific’s Precision SCS system. Nevro denies that the statement quoted in paragraph 25 of the Third Amended Complaint from Nevro’s February 29, 2016 Form 10-K filing evidences that “it is standard practice in the SCS industry to monitor competitors’ patent portfolios.” Nevro lacks sufficient knowledge or information regarding other companies’ practices with respect to monitoring competitors’ patent portfolios,

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.